VAC089
Research type
Research Study
Full title
A Phase Ia clinical trial to assess the safety and immunogenicity of the blood-stage malaria candidate vaccines RH5.1 in Matrix-MTM and R78C in Matrix-MTM, both alone and in combination, in healthy UK adults
IRAS ID
1005709
Contact name
Angela Minassian
Contact email
Sponsor organisation
University of Oxford
Clinicaltrials.gov Identifier
Research summary
Malaria is an infectious disease caused by a parasite which is spread by the bite of an infected mosquito. There were around 240 million cases of malaria and 627,000 deaths worldwide in 2020. There is a great need for a safe, effective malaria vaccine and the team at University of Oxford is trying to make vaccine(s) which can prevent serious illness and death.
This study is being done to evaluate two experimental malaria vaccines for their safety. We will also look at the body’s immune response to the vaccines. The vaccines we are testing in this study are called “R78C” and “RH5.1”. They are given with an adjuvant called “Matrix-M”. An adjuvant is a substance to improve the body’s response to a vaccination.
The aim is to use the vaccines and adjuvant to help the body make an immune response against parts of the malaria parasite. This study will assess:
1. The safety of the vaccines in healthy participants.
2. The response of the human immune system to the vaccines.We will do this by giving healthy adult participants (aged 18-45) three or four doses of the vaccines at the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital in Oxford. We will then do blood tests and collect information about any symptoms that occur after vaccination. There will be 19 to 23 visits, lasting between 12 to 20 months.
REC name
London - Harrow Research Ethics Committee
REC reference
22/LO/0715
Date of REC Opinion
15 Dec 2022
REC opinion
Further Information Favourable Opinion